United States · Platforms & data · MarketBeat
United Therapeutics Prepares for TYVASO Expansion After $833 Million Quarter

Detailed summary
United Therapeutics (NASDAQ:UTHR) is preparing for a potential expansion of its TYVASO franchise into idiopathic pulmonary fibrosis, while its executives pointed to strong third-quarter sales and a pipeline of regulatory and clinical milestones at the UBS London Healthcare Conference. The company r
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)



